TSTL Tristel plc
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. It operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. The company offers device decontamination products, including wipes system, ULT, OPH, Stella system, fuse for Stella, rinse assure, clean, EVE, medistel, EVA system, daisygrip, fuse for surfaces, dosing system, airstel, enzystel, DOK, pre-clean wipes, rinse wipes, sporicidal wipes, clean for Stella, protect, and wipes; surface disinfection products, such as FUSE, JET, JET LUX, JET PRO, TANK 10 CLO2, TANK 5 CLO2, and TILT 5 CLO2; as well as operates 3T, a cloud-based platform alternative to paper-based traceability systems. It provides its medical disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Tristel (LON: TSTL)
›
Tristel (LON: TSTL) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 282 employees.
The shares were at 387.50 GBp on 20 November 2026, up 4.8% over 52 weeks. Its 52-week range is 350.00 GBp to 450.00 GBp: the price is 13.9% below the high and 10.7% above the low.
At a market capitalisation of 186.28M GBP, it trades at 22.8 times trailing earnings and 17.8 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 48.3, a discount of 53% for TSTL. It pays a dividend yielding 3.69% (it pays out 86% of its earnings), against a median of 0.92% among the dividend payers in that peer group.
Tristel reports return on equity of 23.2%, an operating margin of 21.9% and revenue up 6.6% year over year.
It holds more cash than debt, a net cash position of 10.15M GBP. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 6 analysts cover the stock; their mean price target of 470.67 GBp is 21.5% above the current price.